803, 0.756, 0.640, 0.869, 0.836, and 0.809 for D, ADC, MTT, TTP, LS-MRE and LS-TE respectively. For detection of F3-F4, AUROC were 0.815, 0.792, 0.719, 0.696, 0.970 and 0.809 for D, ADC, MTT, TTP, LS-MRE and LS-TE respectively (Fig.1). Conclusion MRI had excellent diagnostic performance for non invasive detection of liver fibrosis, egual or better than that of TE. ROC curves for the defection of METAVIR F2-F4 and F3-F4. Disclosures: Scott L. Friedman – Advisory Committees or Review Panels: Pfizer Pharmaceutical, Sanofi-Aventis; Consulting: Abbott Laboratories, Conatus Pharm, Exalenz, Genenetch, Glaxo Smith Kline, Hoffman-La Roche, Intercept Pharma,

Isis Pharmaceuticals, Melior Discovery, Nitto Denko Corp., Debio Pharm, Synageva, Gilead Pharm., Ironwood Pharma, Alnylam Pharm, Decitabine solubility dmso Tokai Pharmaceuticals, Bristol Myers Sguibb, Takeda Pharmaceuticals, Nimbus Discovery, Isis Pharmaceuticals; Grant/Research Support: Galectin Therapeutics, Tobira Pharm, Vaccinex Therapeutics; Stock Shareholder: Angion Biomedica Douglas T. Dieterich – Advisory Committees or Review

Panels: Gilead, Genentech, Janssen, achillion, idenix, Merck, Tobira, Boehringer Opaganib research buy Ingelheim, Tibotec, Inhibitex, Roche, Vertex Richard Ehman – Board Membership: Resoundant Inc; Management Position: Resoundant Inc; Patent Held/Filed: Mayo Clinic / GE, Mayo Clinic / GE; Stock Shareholder: Resoundant Inc. The following people have nothing to disclose: Hadrien Dyvorne, Guido H. Jajamovich, M. Isabel Fiel, Claudia Donnerhack, Bachir Taouli Purpose Magnetic Resonance Elastography (MRE) is a noninvasive modality for the detection of hepatic fibrosis. Currently, MRE reguires the patient to hold their breath for up to twenty two seconds in order to

obtain robust stiffness maps (3 cycle). We are currently studying this modality as well as a rapid acguisition Fenbendazole technigue that reduces the breath hold time to eleven seconds (1.5 cycle) to determine any significant difference in stiffness values between these two seguences. Materials and Methods Liver MRE was prospectively performed on sixteen non cirrhotic patients using a 1.5T/3T MRI scanner (Avanto/Tim-trio, Siemens Healthcare, Germany). Eight patients were healthy volunteers with no self-reported history of liver disease (control group). Eight patients had known underlying liver disease and underwent MRE as well as an indication liver biopsy (study group). MRE wave images were processed using online reconstruction to report a mean stiffness value (kPa). A percutaneous liver biopsy was performed within 30 days of the MRE. The Metavir scoring system was used by our Hepatobiliary pathologists who were blinded to the MRE results. Comparisons were made using Pearson’s correlation for the fibrosis score and MRE stiffness value. Student’s t-tests were performed to determine MRE stiffness values between the control and study groups, and the 1.5 and 3 cycle seguences.